StudyFinder

MT2025-26: A LONG-TERM FOLLOW-UP STUDY IN PATIENTS WITH HEMOGLOBINOPATHY WHO RECEIVED AUTOLOGOUS CD34+ EDITED HEMATOPOIETIC STEM CELLS

Status: Recruiting

To evaluate the long-term safety of BEAM-101 up to 15 years after treatment.

I'm interested

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• received BEAM-101 in Study BTX-AUT-001 and are in the process of completing the last visit for the study
Conditions:

Blood Disorders

Keywords:

BEAM-101, Sickle cell disease

Study Contact: Ashish Gupta - gupta461@umn.edu
Principal Investigator: Ashish Gupta
IRB Number: STUDY00026462

Back